Search
Methyprylon
go.drugbank.com/drugs/DB01107ApprovedIllicitWithdrawnHowever, with the introduction of newer drugs with fewer side effects, such as benzodiazepines, the clinical use of methyprylon is now limited.
Landiolol
go.drugbank.com/drugs/DB12212ApprovedInvestigational[A264733,A264738] First approved in Japan in 2002 [A264758] for the treatment of intraoperative tachyarrhythmias,[A264733] landiolol was approved in Canada in April 2024 [L51938] and in the US in November
LX201
go.drugbank.com/drugs/DB04943InvestigationalIt is being developed by Lux Biosciences, Inc. … LX201 is a silicone matrix ocular implant that provides sustained release of cyclosporine A (CsA) locally to the eye over the course of one year.
Paromomycin
go.drugbank.com/drugs/DB01421ApprovedInvestigationalAn oligosaccharide antibiotic produced by various streptomyces. [PubChem]
Propylene glycol
go.drugbank.com/drugs/DB01839ApprovedInvestigationalA clear, colorless, viscous organic solvent and diluent used in pharmaceutical preparations.
Mixtures: Family Care Single-Use Eye, CVS Single Use Lubricant Eye DropsEtizolam
go.drugbank.com/drugs/DB09166InvestigationalIt is not approved for use by FDA in the US; however it remains unscheduled in several states and is legal for research purposes.
Glymidine
go.drugbank.com/drugs/DB01382ApprovedIt is used for the concomitant use with insulin for the treatment of noninsulin-dependent (type 2) diabetes mellitus. … Glycodiazine is used with diet to lower blood glucose by increasing the secretion of insulin from pancreas and increasing the sensitivity of peripheral tissues to insulin.
Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine
go.drugbank.com/drugs/DB10061ApprovedInvestigational[L43518] Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine, marketed as MENVEO, was first approved by the FDA in 2010.[L43518] … Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine is used to prevent invasive meningococcal disease, which is caused by bacteria _Neisseria meningitidis_ entering
mRNA-1010
go.drugbank.com/drugs/DB22484ApprovedMFLUSIVA (influenza vaccine, mRNA), also known by its development code mRNA-1010, is a messenger RNA–based vaccine for active immunization against seasonal influenza.
Mitapivat
go.drugbank.com/drugs/DB16236ApprovedInvestigational[A245478] On January 5, 2026, the FDA also approved the use of in the treatment of anemia in adults with alpha- or beta-thalassemia, making it the first oral treatment for this condition.[L54953]